[en] The present study aimed to develop a radiopharmaceutical consisting of an emitter positrons radionuclide ("6"8Ga) which is used in imaging by positron emission tomography; and a peptide capable of binding to somatostatin receptors subtypes 2, 3 and 5; which together serve as a diagnostic support of tumors of neuroendocrine origin. The peptide characterization DOTA-1-Naphthylalanine"3-Octreotide (DOTA-NOC) by infrared spectroscopy technique by Fourier transform was performed, in which the principal functional groups belonging to this molecule were identified as well as its identification by UV-Vis spectroscopy. Subsequently, a variance analysis taking into account three different levels of amounts of sodium acetate, and three different levels of amounts of the peptide was performed. These masses were subjected to lyophilization for a period of 21 h; after completion of lyophilization, were labeled with 2 m L of "6"8GaCl_3 eluates of a "6"8Ge/"6"8Ga ITG generator to determine the percentage of radiochemical purity of the different formulations. It was observed that the ideal formulation must contain 75 μg of peptide and 14 mg of NaOAc, according to studies, was determined that the amount of peptide does not influence the response of radiochemical purity in the same way that the amount of added sodium acetate, which produces different effects on the dependent variable. Finally the radiopharmaceutical formulation was obtained with greater than 95% of radiochemical purity. The validation of the analytical method was performed describing the system accuracy and linearity, specificity and accuracy; linearity and precision of the method, taking into account acceptance criteria based on the guidance of validation of analytical methods published by the National Association of Pharmacists Chemical Biologists of Mexico, A. C.; the parameters evaluated met the specifications given by the guide validation of analytical methods. Uptake and internalization tests of the radiopharmaceutical in AR42J cells were performed, obtaining significant differences in both tests, indicating affinity of the radiopharmaceutical by cells, because they exhibit over expression of SST R2 and 5 receptors. The report of the validation of the production process of the formulation was issued based on the established of the NOM-241-SSA1-2012. (Author)